GlassScriptPhysician profile
Justine Confino
NPI 1881781847
$5,347.04
in general payments reported to CMS, 2019-2025
17 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $971 · 2023: $662 · 2024: $971 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,591.92 | 2021-2025 | |
| Alkermes, INC. | $781.34 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $602.67 | 2021-2025 | Rexulti, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $502.11 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $500.57 | 2021-2025 | Spravato, Invega, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $269.94 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $179.59 | 2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $174.97 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $146.43 | 2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $143.32 | 2021-2023 | |
| Tempus Ai, INC | $125.00 | 2024 | |
| Braeburn INC. | $121.83 | 2025 | Brixadi |
| Eisai INC. | $88.18 | 2021 | |
| Indivior INC. | $44.89 | 2024-2025 | Sublocade, Perseris |
| Allergan, INC. | $29.99 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $25.98 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $18.31 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justine Confino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.